...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment
【24h】

Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment

机译：乳腺癌新辅助治疗中组织病理学，放射性和生物分子变量的一致性评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Neoadjuvant chemotherapy (NAC) for breast cancer (BC) is the gold standard treatment for locally advanced tumors (LABC) that aims at achieving a complete pathological response (pCR). Studies have been conducted to evaluate and identify te concordance between radiological, histopathological and biological variables of BC and final response to therapy, verified by definitive histological examination after surgery. Patients and Methods: Ninety-five BC patients were examined and subjected to NAC. Immunohistochemical markers including oestrogen-receptor (ER), progesterone-receptor (PR), Ki67 index, and human epidermal growth factor receptor 2 (HER2) score were examined before and after neoadjuvant treatment. Results: Younger age and a significant decrease in ER expression were associated with better prognosis. Triple Negative (TN) and Her2-type breast cancers benefited most from neoadjuvant chemotherapy with higher frequency of pCR. Conclusion: HER2-type and TN BC are correlated with best response to NAC. A statistically significant correlation between radiological images and definitive histological examination was not observed.
机译：背景/目的：乳腺癌（BC）的Neoadjuvant化疗（NAC）是局部晚期肿瘤（Labc）的黄金标准治疗，其旨在实现完整的病理反应（PCR）。已经进行了研究以评估和鉴定BC的放射，组织病理学和生物变量与治疗的最终反应之间的一致性，通过手术后明确组织学检查验证。患者和方法：检查95例BC患者并进行NAC。在Neoadjuvant治疗前后检查包括雌激素受体（ER），孕酮受体（PR），KI67指数和人表皮生长因子受体2（HER2）评分的免疫组化标记。结果：年龄较小，ER表达的显着降低与更好的预后相关。三重阴性（TN）和Her2型乳腺癌大部分受益于Neoadjuvant化疗，具有较高的PCR频率。结论：Her2型和TN BC与对NAC的最佳反应相关。未观察到放射图像与明确组织学检查之间的统计学相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号